CVR 26444071Public limited company (A/S)Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900)BallerupFounded 29 Jan 2002
CVR registers no owner holding 5% or more.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about QSI PHARMA A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
8
CVR, 2004
Result
+170K
DKK, annual report 2012
Equity
26.3M
DKK, annual report 2012
CVR registers no owner holding 5% or more.
Lars Olsenuntil 20 Aug 2013
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Q3 2005, quarterly: no employee count, 5 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 2002 | 2003 | 2004 | Q1 2005 | Q2 2005 | Q3 2005 |
|---|---|---|---|---|---|---|
| Employees | 8 | 10 | 8 | No count | No count | No count |
| FTE | 2 | 4 | 4 | 4 | 4 | 5 |
| Series | Annual | Annual | Annual | Quarterly | Quarterly | Quarterly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Q3 2005, published 11 Apr 2006.
The company's own figures, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|
| Operating profit | Not reported | Not reported | Not reported | Not reported | -25 |
| Result for the year | Not reported | Not reported | Not reported | Not reported | +170 |
| Equity | Not reported | Not reported | Not reported | Not reported | 26,264 |
| Total assets | Not reported | Not reported | Not reported | Not reported | 26,346 |
| Credit metrics (Dandex calculations) | |||||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
Annual report 2012
Published 24 Mar 2013
Annual report 2011
Published 28 Mar 2012
Annual report 2010
Published 30 Mar 2011
Annual report 2009
Published 12 Apr 2010
Annual report 2008
Published 31 Mar 2009
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for QSI PHARMA A/S:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 19,999,985, cash price 69.20, implied value 86,505,125 | 69.20 | 19,999,985 | 86,505,125 | 1,250,000 | |
| IncreaseCashPaid in 6,000 | None | 6,000 | None | 961,000 | |
| IncreaseCashPaid in 255,000 | None | 255,000 | None | 955,000 | |
| FoundingNot read from the announcement | None | None | None | 700,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 17 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 17 Nov 2026.
21 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Selskabet er opløst ved en erklæring, jf. selskabslovens § 216.
Bestyrelse:
Udtrådt af bestyrelsen:
Peter Møller Nielsen, den 18.12.2012, Tore Duvold, den 18.12.2012.
Indtrådt i bestyrelsen:
Kristian Merser (formand), den 18.12.2012, Direktør Lars Olsen, den 18.12.2012.
Bestyrelse:
Udtrådt af bestyrelsen:
Jens Hansen, den 09.08.2011.
Indtrådt i bestyrelsen:
Ph.d., Senior Vice President Tore Duvold, den 09.08.2011.
Vedtægter ændret:
31.12.2010.
Bestyrelse:
Udtrådt af bestyrelsen:
Karin Jexner Hamberg, den 16.05.2008.
Indtrådt i bestyrelsen:
Underdirektør Nina Sølver Henning, den 16.05.2008.
Bestyrelse:
Udtrådt af bestyrelsen:
Poul Rødbroe Rasmussen, den 21.01.2008.
Indtrådt i bestyrelsen:
Advokat Peter Møller Nielsen (formand), den 21.01.2008.
Vedtægter ændret:
27.03.2006.
Ny adresse:
c/o Leo Pharma A/S, Industriparken 55, 2750 Ballerup.
Ny kommune:
Ballerup.
Kapitalforhøjelse:
kr. 289.000,00 indbetalt kontant, kurs 6.920,41.
Opdeling i kapitalklasser er ophævet.
Kapitalen udgør herefter kr. 1.250.000,00.
Vedtægter ændret:
13.12.2004.
Vedtægter ændret:
01.09.2004.
Kapitalforhøjelse:
kr. 6.000,00 indbetalt kontant, kurs 100,00,
Klasser:
B kr. 6.000,00.
Kapitalen udgør herefter kr. 961.000,00.
Kapitalen er opdelt i klasser:
A kr. 600.000,00, B kr. 361.000,00.
Vedtægter ændret:
09.06.2004.
Vedtægter ændret:
23.03.2004.
Kapitalforhøjelse:
kr. 255.000,00 indbetalt kontant, kurs 100,00,
Klasser:
B kr. 255.000,00.
Kapitalen udgør herefter kr. 955.000,00.
Kapitalen er opdelt i klasser:
A kr. 600.000,00, B kr. 355.000,00.
Vedtægter ændret:
12.12.2003.
Vedtægter ændret:
28.05.2003.
Revision:
Udtrådt af revisionen:
RSM Christiansen & Engelbrechtsen statsautoriserede revisorer , den 27.03.2003.
Indtrådt i revisionen:
RSM PLUS, STATSAUTORISERET REVISIONSAKTIESELSKAB, Adelgade 15, 2., 1017 København K, den 27.03.2003.
Vedtægter ændret:
29.11.2002.
Vedtægter ændret:
29.05.2002.
Stiftelsesdato:
29.01.2002.
Seneste vedtægtsdato:
29.01.2002.
Kapital:
kr. 700.000,00.
Kapitalen er opdelt i klasser:
A kr. 600.000,00, B kr. 100.000,00.
Indbetalingsmåde:
kontant kr. 600.000,00 til kurs 1.983,33, kontant kr. 100.000,00 til kurs 100,00.
Stifter:
CVR-NR. 56759514 LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB, Industriparken 55, 2750 Ballerup, den 29.01.2002.
Bestyrelse:
Direktør Poul Rødbroe Rasmussen (formand), den 29.01.2002, Læge Karin Hamberg, den 29.01.2002, Professor, cand. pharm., PHD Jens Hansen, den 29.01.2002.
Direktion:
Lars Olsen, den 29.01.2002.
Selskabet tegnes af formanden i forening med den administrerende direktør eller af tre bestyrelsesmedlemmer i forening.
Revision:
RSM Christiansen & Engelbrechtsen Statsautoriserede revisorer, 1304 København K, den 29.01.2002.
Første regnskabsår:
29.01.2002 - 31.12.2002.
Regnskabsår:
01.01 - 31.12.
P-number 1012598021Søltofts Plads 221, 2800 Kgs.Lyngby
P-number 1008922566Søltofts Plads 221, 2800 Kgs.Lyngby